run in TBE £0.5 at room temperature for 2 h at 150 V. The following two (Q/q) 27-bp unmethylated oligonucleotides were used: 5 0 -GATCCTTCGCCTAGGCTC(A/G)CAGCG CGGGAGCGA-3 0 . A methylated q probe (q*) was generated by incorporating a methylated cytosine at the mutated CpG site during oligonucleotide synthesis. Transient transfection assayThe constructs contained 578 bp from IGF2 intron 3 (nucleotides 2868-3446), followed by the IGF2 P3 promoter (nucleotides 2222 to þ45 relative to the start of transcription) 12 and a luciferase reporter. C2C12 myoblast cells were grown to approximately 80% confluence. Cells were transiently co-transfected with the firefly luciferase reporter construct (4 mg) and a Renilla luciferase control vector (phRG-TK, Promega; 80 ng) using 10 mg Lipofectamine 2000 (Invitrogen). Cells were incubated for 25 h before lysis in 100 ml Triton lysis solution. Luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega). The results are based on four triplicate experiments using two independent plasmid preparations for each construct. Statistical analysis was done with an analysis of variance.
A chameleon under pressure: The observed piezochromic behavior of the title compound (BP2VA) was found to depend on its molecular aggregation state and specifically on the strength of the π–π interaction between the anthracene rings of adjacent molecules. When BP2VA is ground or placed under pressure, its molecular aggregation state changes, and a red shift in the fluorescence emission from green via orange to red occurs (see picture).
An ongoing outbreak of 2019‐nCoV pneumonia was first identified in Wuhan, Hubei province, China at the end of 2019. With the spread of the new coronavirus accelerating, person‐to‐person transmission in family homes or hospitals, and intercity spread of 2019‐nCoV occurred. At least 40,261 cases confirmed, 23,589 cases suspected, 909 cases death and 3444 cases cured in China and worldwide 24 countries confirmed 383 cases being diagnosed, 1 case death in February 10th, 2020. At present, the mortality of 2019‐nCoV in China is 2.3%, compared with 9.6% of SARS and 34.4% of MERS reported by WHO. It seems the new virus is not as fatal as many people thought. Chinese authorities improved surveillance network, made the laboratory be able to recognize the outbreak within a few weeks and announced the virus genome that provide efficient epidemiological control. More comprehensive information is required to understand 2019‐nCoV feature, the epidemiology of origin and spreading, and the clinical phenomina. According to the current status, blocking transmission, isolation, protection, and alternative medication are the urgent management strategies against 2019‐nCoV.
Quantum dots have been used in biomedical research for imaging, diagnostics and sensing purposes. However, concerns over the cytotoxicity of their heavy metal constituents and conflicting results from in vitro and small animal toxicity studies have limited their translation towards clinical applications. Here, we show in a pilot study that rhesus macaques injected with phospholipid micelle-encapsulated CdSe/CdS/ZnS quantum dots do not exhibit evidence of toxicity. Blood and biochemical markers remained within normal ranges following treatment, and histology of major organs after 90 days showed no abnormalities. Our results show that acute toxicity of these quantum dots in vivo can be minimal. However, chemical analysis revealed that most of the initial dose of cadmium remained in the liver, spleen and kidneys after 90 days. This means that the breakdown and clearance of quantum dots is quite slow, suggesting that longer-term studies will be required to determine the ultimate fate of these heavy metals and the impact of their persistence in primates.
Tremendous research efforts have been devoted to fabricating high quality quantum dots (QDs) for applications in biology and medicine. Much of this research was pursued with an ultimate goal of using QDs in clinical applications. However, a great deal of concern has been voiced about the potential hazards of QDs due to their heavy-metal content. Many studies have demonstrated toxicity of various QDs in cell culture studies. However, in a smaller number of studies using small animal models (mice and rats), no abnormal behaviour or tissue damage was noticed over periods of months after the systemic administration of QDs. Nevertheless, the correlation of these results with the potential for negative effects of QD on humans remains unclear. Many urgent questions must be answered before the QDs community moves into the clinical research phase. This review provides an overview of the toxicity assessment of QDs, ranging from cell culture studies to animal models and discusses their findings. Guidelines for using various nonhuman primate models for QD toxicity studies are highlighted. This review article is intended to promote the awareness of current developments of QD applications in biology, the potential toxicity of QDs, and approaches to minimizing toxicity.
The dentin matrix protein-1 (DMP-1) gene is identified in odontoblasts during both embryonic and postnatal development. In vitro study suggests that this noncollagen acidic phosphoprotein plays a role in mineralization. However, deletion of the Dmp-1 gene has little effect on tooth development during embryogenesis. To address the role of DMP-1 in tooth during postnatal development, we analyzed changes of dentinogenesis in Dmp-1 null mice from 3 days after birth to 1 year. Here we show that Dmp-1 null mice postnatally develop a profound tooth phenotype characterized by a partial failure of maturation of predentin into dentin, enlarged pulp chambers, increased width of predentin zone with reduced dentin wall, and hypomineralization. The tooth phenotype of these mice is strikingly similar to that in dentin sialophosphoprotein (Dspp) null mice and shares some features of the human disease dentinogenesis imperfecta III. We have also demonstrated that DSPP levels are reduced in Dmp-1 null mice, suggesting that DSPP is probably regulated by DMP-1 during dentinogenesis. Finally, we show the absence or delayed development of the third molar in Dmp-1 null mice, which is probably secondary to defects in Dmp-1 null bone. Taken together, these studies suggest that DMP-1 is essential for later dentinogenesis during postnatal development.Dentin is a mineralized tissue that closely resembles bone in composition and mechanism of formation. The mechanisms for mineralization are largely unclear, although two hypotheses are proposed to explain initiating mineralization: matrix vesicles in mantle dentin and collagen-phosphophoryn complexes in circumpulpal dentin (1). The in vitro studies also suggest that phosphorylated extracellular matrix (ECM) 1 proteins localized within collagen gap zones can bind calcium and phosphate ions in an appropriate conformation to nucleate the formation of apatite crystals (2, 3). One of the noncollagenous proteins that appears to play an important role in dentin ECM formation and mineralization is dentin matrix protein-1 (DMP-1).DMP-1, an acidic phosphorylated extracellular matrix protein (4), is expressed in odontoblasts that secrete matrix proteins to form dentin. Using protein chemistry approaches, some progress has been made in identifying the normally processed forms of DMP-1 in mineralized tissues (5). Although full-length DMP-1 has been cloned and sequenced, the corresponding intact protein has not been isolated from mineralized tissues. However, two proteolytic fragments, a 37-kDa N-terminal fragment and a 57-kDa C-terminal fragment, have been isolated from bone and dentin extracts (5). Recent studies suggest that DMP-1 can be cleaved by bone morphogenetic protein-1/tolloidlike proteinases (6).In vitro studies suggest that overexpression of Dmp-1 induces differentiation of mesenchymal cells to odontoblast-like cells and enhances mineralization (7) and that DMP-1 can bind to Ca 2ϩ and initiate mineral deposition in vitro (8). However, effects of recombinant DMP-1 on in vitro mineralization are ...
Bone morphogenetic proteins (BMPs) are known to induce ectopic bone. However, it is largely unknown how BMP signaling in osteoblasts directly regulates endogenous bone. This study investigated the mechanism by which BMP signaling through the type IA receptor (BMPR1A) regulates endogenous bone mass using an inducible Cre-loxP system. When BMPR1A in osteoblasts was conditionally disrupted during embryonic bone development, bone mass surprisingly was increased with upregulation of canonical Wnt signaling. Although levels of bone formation markers were modestly reduced, levels of resorption markers representing osteoclastogenesis were severely reduced, resulting in a net increase in bone mass. The reduction of osteoclastogenesis was primarily caused by Bmpr1a-deficiency in osteoblasts, at least through the RANKL-OPG pathway. Sclerostin (Sost) expression was downregulated by about 90% and SOST protein was undetectable in osteoblasts and osteocytes, whereas the Wnt signaling was upregulated. Treatment of Bmpr1a-deficient calvariae with sclerostin repressed the Wnt signaling and restored normal bone morphology. By gain of Smad-dependent BMPR1A signaling in mice, Sost expression was upregulated and osteoclastogenesis was increased. Finally, the Bmpr1a-deficient bone phenotype was rescued by enhancing BMPR1A signaling, with restoration of osteoclastogenesis. These findings demonstrate that BMPR1A signaling in osteoblasts restrain endogenous bone mass directly by upregulating osteoclastogenesis through the RANKL-OPG pathway, or indirectly by downregulating canonical Wnt signaling through sclerostin, a Wnt inhibitor and a bone mass mediator.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.